Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiolite Stress MPI for Asymptomatic Restenosis in Diabetic Patients
NCT00162357Phase 4Completed
- Sponsor
- Lantheus Holdings, Inc.
- Start
- Apr 2004
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of Tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate in coronary restenosis (2 arms), sponsored by Lantheus Holdings, Inc. Primary endpoint: Evaluate symptom-free heart blockages that develop following initial opening based on Cardiolite imaging. Started Apr 2004; status: completed.
02
Drugs
Tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate
03
Conditions
coronary restenosis
Beyond the preview
Go deeper on NCT00162357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162357.